Almuhtaseb H - Search Results

1

An Exploratory Study Provides Insights into MMP9 and Aβ Levels in the Vitreous and Blood across Different Ages and in a Subset of AMD Patients.

Lynn SA, Soubigou F, Dewing JM, Smith A, Ballingall J, Sass T, Nica I, Watkins C, Gupta B, Almuhtaseb H, Lash SC, Yuen HM, Cree A, Newman TA, Lotery AJ, Ratnayaka JA. Lynn SA, et al. Among authors: almuhtaseb h. Int J Mol Sci. 2022 Nov 23;23(23):14603. doi: 10.3390/ijms232314603. Int J Mol Sci. 2022. PMID: 36498929 Free PMC article.

2

Reply to: 'Comment on: 'One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration'.

Almuhtaseb H, Lotery A. Almuhtaseb H, et al. Eye (Lond). 2018 Feb;32(2):479-481. doi: 10.1038/eye.2017.212. Epub 2017 Oct 20. Eye (Lond). 2018. PMID: 29052610 Free PMC article. No abstract available.

3

Socio-economic status and outcomes for patients with age-related macular degeneration.

More P, Almuhtaseb H, Smith D, Fraser S, Lotery AJ. More P, et al. Among authors: almuhtaseb h. Eye (Lond). 2019 Aug;33(8):1224-1231. doi: 10.1038/s41433-019-0393-3. Epub 2019 Mar 11. Eye (Lond). 2019. PMID: 30858565 Free PMC article.

4

Second-year visual acuity outcomes of nAMD patients treated with aflibercept: data analysis from the UK Aflibercept Users Group.

Almuhtaseb H, Johnston RL, Talks JS, Lotery AJ. Almuhtaseb H, et al. Eye (Lond). 2017 Nov;31(11):1582-1588. doi: 10.1038/eye.2017.108. Epub 2017 Jun 16. Eye (Lond). 2017. PMID: 28622328 Free PMC article. Clinical Trial.

5

One-year real-world outcomes in patients receiving fixed-dosing aflibercept for neovascular age-related macular degeneration.

Almuhtaseb H, Kanavati S, Rufai SR, Lotery AJ. Almuhtaseb H, et al. Eye (Lond). 2017 Jun;31(6):878-883. doi: 10.1038/eye.2017.6. Epub 2017 Feb 10. Eye (Lond). 2017. PMID: 28186507 Free PMC article. Clinical Trial.

6

Evaluation of Pro-re-Nata (PRN) and Treat and Extend Bevacizumab treatment protocols in Sorsby Fundus Dystrophy.

Tsokolas G, Almuhtaseb H, Lotery A. Tsokolas G, et al. Among authors: almuhtaseb h. Eur J Ophthalmol. 2020 Jan;30(1):26-33. doi: 10.1177/1120672118811568. Epub 2018 Nov 13. Eur J Ophthalmol. 2020. PMID: 30421618

7

A systematic review to assess the 'treat-and-extend' dosing regimen for neovascular age-related macular degeneration using ranibizumab.

Rufai SR, Almuhtaseb H, Paul RM, Stuart BL, Kendrick T, Lee H, Lotery AJ. Rufai SR, et al. Among authors: almuhtaseb h. Eye (Lond). 2017 Sep;31(9):1337-1344. doi: 10.1038/eye.2017.67. Epub 2017 May 5. Eye (Lond). 2017. PMID: 28475181 Free PMC article. Review.

8

Choroidal neovascularization post macular surgery: a case series.

Tsokolas G, Clarke B, Almuhtaseb H, Gupta B. Tsokolas G, et al. Among authors: almuhtaseb h. Int J Ophthalmol. 2018 Aug 18;11(8):1425-1429. doi: 10.18240/ijo.2018.08.28. eCollection 2018. Int J Ophthalmol. 2018. PMID: 30140652 Free PMC article. No abstract available.

9

Macular toxicity secondary to occupational exposure to gold melting.

Almuhtaseb H, Tsokolas G, Lotery A, Jalil A. Almuhtaseb H, et al. Eye (Lond). 2019 Oct;33(10):1667-1669. doi: 10.1038/s41433-019-0471-6. Epub 2019 May 20. Eye (Lond). 2019. PMID: 31110231 Free PMC article. No abstract available.

10

Long term follow-up of a family with GUCY2D dominant cone dystrophy.

Tsokolas G, Almuhtaseb H, Griffiths H, Shawkat F, Pengelly RJ, Sarah E, Lotery A. Tsokolas G, et al. Among authors: almuhtaseb h. Int J Ophthalmol. 2018 Dec 18;11(12):1945-1950. doi: 10.18240/ijo.2018.12.12. eCollection 2018. Int J Ophthalmol. 2018. PMID: 30588428 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

12 results

Search Page